LAUSANNE, Switzerland, May 15 Debiopharm Group(Debiopharm), a global independent biopharmaceutical development specialistfocusing on serious medical conditions and particularly oncology, announcedthe signature of a license agreement with its long-term Europeanpharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-monthformulation, a gonadotropin releasing hormone (GnRH) agonist analogue,effective in the treatment of severe sexual deviations in adult men byinducing and maintaining a reversible reduction of testosterone to castrateserum levels. Debiopharm has developed and received marketing authorisationsfor Salvacyl / Moapar in nine major European countries, including France,Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.
"There is a genuine unmet medical and social need for the treatment ofsexual deviations. Not many pharma companies are willing or courageous enoughto provide this type of treatment but we feel that we have a responsibilityto help doctors and patients with the tools they need, even if it isdifficult or controversial," said Rolland-Yves Mauvernay, President andFounder of Debiopharm Group.
In the treatment of sexual deviations in men, administration ofSalvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms orintra-muscular weekly injections required with antiandrogens such ascyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there arefewer side effects.
Two studies have shown that regular injections of the active ingredient,triptorelin, over a period of eight months to seven years in male patientswith sexual deviations demonstrated a good efficacy and safety profile.Triptorelin produced reversible serum castrate testosterone levels (definedas less than or equal to 1.735 nmol/L) in all patients, and concurrently withthe decrease in testosterone levels, triptorelin treatment reduced deviantsexual behaviours in 35/36 patients with severe sexual deviations.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialistthat in-licenses promising biologics and small molecule drug candidates.Debiopharm develops its products for global registration and maximumcommercial potential for out-licensing to pharmaceutical partners for salesand marketing.
Debiopharm independently funds the worldwide development of all of itsproducts while providing expertise in pre-clinical and clinical trials,manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharmhas developed three products with global combined sales in excess of $2.65billion in 2007.For more information on Debiopharm Group, please visit:http://www.debiopharm.com. Debiopharm S.A. Contacts Kim Bill VP, Corporate Development Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 [email protected]
Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 [email protected]
In New York Russo Partners, LLC Wendy Lau Tel: +1-212-845-4272 Fax: +1-212-845-4260 [email protected]
SOURCE The Debiopharm Group